NIH-funded research NIH-funded research

Isolating stem cells from sickle cell disease patients for gene therapy

Official title: Precision Apheresis: stem cell isolation from patients with sickle cell disease for gene therapy using high-throughput microfluidics

Funded at Massachusetts General Hospital · NIH-10899569 · Data updated 2026-11-12

This study is working on a new way to collect important stem cells from the blood of people with sickle cell disease, which could help improve gene therapy treatments by making sure we get more of these valuable cells.

More Sickle Cell Disease research and trials

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionMassachusetts General Hospital
NIH-funded
Lab location1 site (Boston, United States)
Project startAugust 5, 2023
Project endJuly 31, 2028
Funding year2024
Award (this year)$137,183
NIH project number5K25HL169816-02
Project IDNIH-10899569 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with sickle cell disease who require stem cell therapy.

Less likely to help

Patients who do not have sickle cell disease or those who are not candidates for stem cell therapy may not benefit from this research.

What this research studies

This research focuses on developing a new technology to efficiently isolate hematopoietic stem and progenitor cells (HSPCs) from the blood of patients with sickle cell disease. By using a microfluidic device, the study aims to recover a high percentage of valuable stem cells from apheresis products, which are crucial for successful gene therapy. The approach involves genetic editing of these isolated stem cells and testing their effectiveness in animal models. This innovative method seeks to overcome current challenges in stem cell purification that can lead to significant cell loss.

Why it matters

Potential benefit: If successful, this research could significantly improve the availability and quality of stem cells for gene therapy in sickle cell disease patients, potentially leading to better treatment outcomes.

How similar studies have gone: Other research has shown promise in using microfluidic technologies for cell isolation, indicating potential success for this novel approach.

Where this research is happening

  • Massachusetts General Hospital
    Boston, United States
    Active

Researchers

  • Principal investigator: Mishra, Avanish — Massachusetts General Hospital
  • Study coordinator: Mishra, Avanish

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.